Moxifloxacin (as HCl) 400mg/250mL; soln for IV infusion; latex- and preservative-free. Moxifloxacin inhibits topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial ...

and moxifloxacin intravenous infusion for the treatment of complicated skin and skin structure infections caused by methicillin-susceptible bacteria. On July 22, the FDA approved ramelteon 8-mg ...

intravenous-to-oral moxifloxacin in patients with CABP ... solithromycin was found to have a higher incidence of mild to moderate infusion-related adverse events. If approved, solithromycin ...

Moxifloxacin IV infusion is approved to treat Community Acquired Pneumonia (CAP) and Complicated Skin and Skin Structure Infections (cSSSI) caused by methicillin susceptible Staphylococcus aureus ...

In this Solitaire-IV Phase 3 clinical trial ... versus 2.1% for moxifloxacin). Study drug discontinuation due to non-infusion related adverse events was comparable between study arms (3.5% ...

Medicare covers intravenous (IV) infusion therapy when a doctor prescribes it as medically necessary. Original Medicare Part A typically covers the costs if you have an IV infusion during an ...